Regenix is a Chennai-based biopharmaceutical company manufacturing sterile injectable biosimilars — formulation, sterile fill-finish, bioequivalence and regulatory submission, all delivered end-to-end from a single integrated facility at MEPZ-SEZ.
Regenix Biosciences was incorporated in 2018 at MEPZ-SEZ Chennai as the biosimilar division of the Regenix Group — an integrated Indian pharmaceutical group built across pharma, retail pharmacy, diagnostics and biotech, promoted by Dr. A. Ramamurthy and a network of more than 2,500 medical doctors.
From day one in biosimilars, we chose vertical integration — formulation, sterile fill-finish, clinical bioequivalence and regulatory filing — all delivered under one roof. Not because it was easy, but because it was the only way to control quality, cost and timeline end-to-end.
The Group's pharmaceutical experience now sits behind every batch Regenix Biosciences releases. Four CDSCO Marketing Authorisations across the diabetes franchise and an eight-product biosimilar portfolio overall. Active exports across four regions. A pipeline targeting 120+ markets by 2028. And a quality culture, not a quality department, woven into every step of the chain.
Our purpose, mission, vision and the four principles that govern every decision.
Read more →From 2007 to today — the Regenix Group's heritage and the biosimilar mission.
View timeline →The leadership team behind Regenix's clinical, regulatory and commercial strategy.
Meet the board →Distribution partners, licensing engagements, contract manufacturing, regional licensing — wherever you sit in the value chain, we're ready to engage.